PREDICTSCRIPT

Serial Number 97091070
Registration 7697879
700

Registration Progress

Application Filed
Oct 25, 2021
Under Examination
Nov 14, 2023
Approved for Publication
Sep 19, 2023
Published for Opposition
Sep 19, 2023
Registered
Feb 18, 2025

Trademark Image

PREDICTSCRIPT

Basic Information

Serial Number
97091070
Registration Number
7697879
Filing Date
October 25, 2021
Registration Date
February 18, 2025
Published for Opposition
September 19, 2023
Drawing Code
4

Status Summary

Current Status
Active
Status Code
700
Status Date
Feb 18, 2025
Registration
Registered
Classes
042

Rights Holder

Phenomics Health Inc.

03
Address
46701 Commerce Center Drive
Plymouth, MI 48170

Ownership History

Phenomics Health Inc.

Original Applicant
03
Plymouth, MI

Phenomics Health Inc.

Owner at Publication
03
Plymouth, MI

Phenomics Health Inc.

Original Registrant
03
Plymouth, MI

Legal Representation

Attorney
ROGER H. BORA

USPTO Deadlines

Next Deadline
1870 days remaining
Section 8 Declaration Due (Principal Register) (Based on registration date 20250218)
Due Date
February 18, 2031
Grace Period Ends
August 18, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

49 events
Date Code Type Description Documents
Feb 18, 2025 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED Loading...
Feb 18, 2025 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Jan 27, 2025 SUNA E NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED Loading...
Jan 27, 2025 CNPR P ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED Loading...
Jan 24, 2025 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Jan 24, 2025 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Jan 24, 2025 ALIE A ASSIGNED TO LIE Loading...
Jan 13, 2025 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Jan 13, 2025 XELG O APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED Loading...
Jan 13, 2025 XELR I APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED Loading...
Oct 15, 2024 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Oct 15, 2024 GNRT O NON-FINAL ACTION E-MAILED Loading...
Oct 15, 2024 CNRT W SU - NON-FINAL ACTION - WRITTEN Loading...
Jun 15, 2024 SUPC I STATEMENT OF USE PROCESSING COMPLETE Loading...
May 13, 2024 IUAF S USE AMENDMENT FILED Loading...
Jun 15, 2024 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
May 13, 2024 EISU I TEAS STATEMENT OF USE RECEIVED Loading...
May 11, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
May 10, 2024 EX1G S SOU EXTENSION 1 GRANTED Loading...
May 10, 2024 EXT1 S SOU EXTENSION 1 FILED Loading...
May 10, 2024 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Nov 14, 2023 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Oct 20, 2023 EXPT T EXPARTE APPEAL TERMINATED Loading...
Oct 19, 2023 EXPT T EXPARTE APPEAL TERMINATED Loading...
Oct 19, 2023 EXDM T EXPARTE APPEAL DISMISSED AS MOOT Loading...
Sep 19, 2023 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Sep 19, 2023 PUBO A PUBLISHED FOR OPPOSITION Loading...
Aug 30, 2023 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Aug 15, 2023 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Aug 8, 2023 EXPI T EX PARTE APPEAL-INSTITUTED Loading...
Aug 8, 2023 JURT T JURISDICTION RESTORED TO EXAMINING ATTORNEY Loading...
Aug 8, 2023 EXAF T EXPARTE APPEAL RECEIVED AT TTAB Loading...
Aug 3, 2023 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Aug 3, 2023 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Aug 3, 2023 ERFR I TEAS REQUEST FOR RECONSIDERATION RECEIVED Loading...
Apr 27, 2023 XELG O APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED Loading...
Apr 27, 2023 XELR I APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED Loading...
Feb 10, 2023 GNFN O NOTIFICATION OF FINAL REFUSAL EMAILED Loading...
Feb 10, 2023 GNFR O FINAL REFUSAL E-MAILED Loading...
Feb 10, 2023 CNFR R FINAL REFUSAL WRITTEN Loading...
Jan 4, 2023 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Jan 4, 2023 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Jan 4, 2023 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Jul 5, 2022 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Jul 5, 2022 GNRT F NON-FINAL ACTION E-MAILED Loading...
Jul 5, 2022 CNRT R NON-FINAL ACTION WRITTEN Loading...
Jun 15, 2022 DOCK D ASSIGNED TO EXAMINER Loading...
Nov 8, 2021 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Oct 28, 2021 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 042
Scientific and technological services in the field of pharmaceuticals featuring scientific testing, analysis and evaluation of blood samples for the purpose of drug development by others, namely, data-driven analytics and reporting to developers of drugs; scientific and technological services in the field of pharmaceuticals featuring scientific testing, analysis and evaluation of blood samples for the purpose of improving quality in the field of healthcare services, specifically for improving the monitoring and diagnostics of quantitative patient drug exposure, the monitoring and diagnostics of patient drug compliance, data-driven analytics and reporting to providers of healthcare services in the field of pharmacovigilance activities, drug dosage recommendations, initial drug prescribing, and drug switching, all for research purposes and not for medical purposes; genetic testing for scientific research purposes, specifically pharmacogenomic testing, analysis, and evaluation of buccal, saliva and other biological samples for the purposes of analyzing how the genetic makeup of an individual affects their response to drugs, improving drug selection and dosage recommendations, selecting initial and subsequent medications, identifying drug-drug interactions, avoiding adverse drug reactions, developing clinical treatment decision support recommendations, and supporting other medical diagnostic products and prescription drugs; genetic testing for scientific research purposes, namely, analysis of multiple genes and genetic variants and their effect on drug response across multiple therapeutic areas, including but not limited to psychiatry, pain, cardiology, and oncology; scientific and technological services in the field of pharmaceuticals in the nature of scientific testing, analysis and evaluation of biological samples for research purposes, specifically research in the field of clinical trials, and research in the field of new drug development and drug repurposing
First Use Anywhere: 20230200
First Use in Commerce: 20230200

Additional Information

Pseudo Mark
PREDICT SCRIPT

Classification

International Classes
042